Informazioni
Non ci sono recensioni
What Is Cancer of the Rectum?
Pages 1-8
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Multidisciplinary Management of Rectal Cancer
Questions and Answers
Valentini, Schmoll, van de Velde,
Editore
Springer
Anno
2018
Pagine
634
ISBN
9783319432151
170,00 €
DA SCONTARE
In this book, a distinguished group of clinicians provide straightforward, focused answers to the questions most commonly confronted by a multidisciplinary team when caring for patients with rectal cancer. The format of the book is designed to aid optimal decision making in a multidisciplinary setting with respect to key issues in imaging, radiotherapy, chemotherapy, and surgery, all of which are considered in detail. Helpful guidance is also offered on risk factor identification, pathology procedures and their prognostic value, and multidisciplinary team management. The authors have been carefully selected for their expertise, and most have been involved in the management of the more significant trials published in Europe during the past decade.
In an era in which all patients are entitled to access healthcare systems that deliver the highest quality of treatment within a safe environment, together with appropriate advice, support, and long-term follow-up, the multidisciplinary team is of central importance. This successful book, in its revised and updated second edition, is designed to provide all the guidance likely to be required by members of the multidisciplinary team at various stages of the pathway of care for patients with rectal cancer.
-
-
The Patient’s Perspective
Pages 9-19
-
What Are the Issues in the Treatment of Elderly Patients?
Pages 21-28
-
Are There Risk Factors in the European Population, Which Promote Rectal Cancer and/or Favour Curability?
Pages 29-36
-
What Is the History of Rectal Cancer Treatment?
Pages 37-44
-
Is TNM Staging the Most Relevant Prognostic Clinical Factor to Consider for Treatment Decisions Before and After Surgery?
Pages 45-50
-
Do Different Populations of Rectal Cancer Exist?
Pages 51-57
-
What Is the Ongoing Recommendation in the Management of Rectal Cancer?
Pages 59-67
-
How Can We Identify Tumour Penetration?
Pages 71-77
-
How Can We Better Identify Mesorectal Fascia Involvement?
Pages 79-85
-
How Can We Identify Nodal Involvement and Extramural Vascular Invasion?
Pages 87-92
-
How Can We Identify the Position of the Positive Nodes in the Different Pelvic Compartments by Imaging?
Pages 93-97
-
How Can We Identify the Presence of Metastases?
Pages 99-106
-
How Can We Identify Pathologic Complete Responders After Chemoradiotherapy?
Pages 107-111
-
How Can We Identify Local Relapse?
Pages 113-119
-
Are There New Molecular Imaging Modalities Behind the Corner?
Pages 121-126
-
Are There Functional Imaging Markers to Consider for Treatment Decision Making?
Pages 127-134
-
How Can Radiomics Improve Clinical Choices?
Pages 135-149
-
When Should Radiation Be Avoided in the Treatment of Rectal Cancer?
Pages 153-158
-
When Should Preoperative Radiochemotherapy Be Performed?
Pages 159-163
-
Should We Tailor the Delineation of Pelvic Structures According to Tumor Presentation?
Pages 165-179
-
Which Margin Should Be Added to the GTV?
Pages 181-186
-
When Should IGRT Be Done?
Pages 187-192
-
What Are the Dose-Volume Constraints for Long-Course Radiochemotherapy to Apply for IMRT?
Pages 193-197
-
What Is the Contribution of Intraoperative Radiotherapy (IORT) in Tailoring Local Therapy in Primary or Recurrent Rectal Cancer?
Pages 199-206
-
What Is the Contribution of Brachytherapy in Tailoring Local Therapy?
Pages 207-215
-
What Are the Minimal QA Procedures to Guarantee a Good RT Treatment
Pages 217-222
-
When Could Preoperative Radiotherapy Be Proposed for cT2 Presentations?
Pages 223-228
-
What Are the Present Recommendations for Short-Course Preoperative Radiotherapy (RT) and Delayed Surgery?
Pages 229-235
-
When Should Postoperative Radiochemotherapy Be Performed?
Pages 237-241
-
Which Side Effects Related to Short-Course Radiotherapy Should Be Described to the Patients Before Treatment?
Pages 243-246
-
Which Side Effects Should Be Described to Patients Before Neoadjuvant Radio-Chemotherapy Treatment?
Pages 247-251
-
Why Do We Have to Use Chemotherapy?
Pages 255-258
-
Are Capecitabine and 5FU Equivalent When Combined with Radiotherapy?
Pages 259-262
-
Should Oxaliplatin Be Added to Preoperative Chemoradiation?
Pages 263-272
-
Should Biological Targeted Agents be Combined with Preoperative Chemoradiation in Rectal Cancer? An Update
Pages 273-285
-
Should Upfront Chemotherapy Precede Preoperative Chemoradiotherapy and Surgery in Locally Advanced Rectal Cancer?
Pages 287-297
-
Could Upfront Chemotherapy Substitute Preoperative Radiochemotherapy?
Pages 299-305
-
Could New Drugs Offer Opportunities to Extend Resectability in Advanced Presentations?
Pages 307-312
-
Will Adjuvant Chemotherapy Improve Outcome After Preoperative (Chemo) Radiotherapy? Still More Passion than Evidence
Pages 313-323
-
Should Oxaliplatin Be Added to 5FU-Based Regimens in Adjuvant Chemotherapy for Locally Advanced Rectal Cancer?
Pages 325-329
-
What Chemotherapy Is Practicable in Aged Patients?
Pages 331-337
-
What Chemotherapy to Recommend in Metastatic Patients?
Pages 339-348
-
Which Side Effect Related to Chemotherapy Should Be Described to the Patients Before Treatment?
Pages 349-354
-
“Are There New Chemotherapy Drugs Behind the Corner?”
Pages 355-358
